Roivant Sciences is evolving from an asset-monetization platform into a commercial-stage biopharma company, supported by a strong cash position of $4.7 billion that reduces near-term dilution risk. The company is preparing to commercialize brepocitinib, which is under FDA Priority Review for dermatomyositis with potential approval expected by September 2026. This drug anchors Roivant's near-term growth prospects, while additional label expansions target a patient population exceeding 280,000. Investors should watch for regulatory developments, capital allocation decisions, and risks related to minority interests as the company leverages its pipeline and financial strength for future growth.
MillerKnoll reported a strong Q1 2027 earnings per share (EPS) of $0.53, surpassing analyst expectations by over 51%, helped by tariff refunds and improved cost management. However, its revenue fell 3.4% year-over-year to $923.40 million, missing est...
THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...
Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...
Salesforce's AI-driven Agentforce business is expanding at over 240% annual recurring revenue growth, yet its stock trades like a legacy CRM company, down 9.6% year-to-date. The company reported strong Q2 FY27 results with $11.35 billion revenue and ...
Stellar (XLM) has broken above its 50-week moving average, signaling strong buying momentum and setting a trading range around $0.2123 to $0.2151, with potential to reach $0.2227 if demand continues. Meanwhile, XRP faces strong selling pressure near ...
